Released Aug 9, 2016, after the close
10-Q filed Aug 9, 2016, 40 days after period end · 0000320017-16-000143
Q2 2015 · 10-Q
Revenue$8.30M$8.30M +41.5% vs Q2 2014+10.8% vs Q1 2015
Net Income-$7.88M-$7.88M N/M vs Q2 2014N/M vs Q1 2015
EPS Diluted-$1.33-$1.33 N/M vs Q2 2014N/M vs Q1 2015
Operating Income-$7,405,824N/M
Operating Cash Flowderived-$6,547,257N/M
Free Cash Flowderived-$6,570,559N/M
Margins · derived
Operating margin-89.2%+348.3 pt vs Q2 2014
Net margin-95.0%−94.7 pt vs Q2 2014
What the release said
The release
Same quarter
| Metric | Q2 2015 | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|---|
| Revenue | $8.30M | $5.87M | $4.49K | — |
| Net Income | -$7.88M | -$17.13K | -$12.61K | -$8.58K |
| EPS Diluted | -$1.33 | -$3.84 | -$0.40 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR